Table 2.

Surgical outcomes by time between discontinuation of anti-fibrotic medication and transplant (N = 297).

Outcome	Time between discontinuation of anti-fibrotic medication and transplant		p-value
	Shorter (n = 211)	Longer (n = 86)
Received intra-operative ECMO/CPB	100 (47.4)	45 (52.3)	0.44
Received post-operative ECMO	21 (10.0)	13 (15.1)	0.20
Received intra-operative PRBCs	94 (44.5)	51 (59.3)	0.021
Units of intra-operative PRBCs a	2.0 (2.0, 4.0)	2.0 (1.0, 4.0)	0.23
Received post-operative PRBCs	59 (28.0)	47 (54.7)	<0.001
Units of post-operative PRBCs b	2.0 (1.0, 4.0)	2.0 (1.0, 3.0)	0.24
Primary graft dysfunction	125 (59.2)	63 (73.3)	0.023
Anastomotic dehiscence	11 (5.2)	0 (0.0)	0.031
Surgical wound dehiscence	8 (3.8)	4 (4.7)	0.73
Sternal dehiscence	12 (5.7)	0 (0.0)	0.024
Transplant to extubation (days)	1.0 (1.0, 2.0)	1.0 (1.0, 3.0)	0.65
Time from transplant to final chest tube removal	11.0 (8.0, 16.0)	12.0 (9.0, 18.0)	0.066
Returned to operating room	55 (26.1)	25 (29.1)	0.60
Length of stay in ICU (days) c	5.0 (3.0, 10.0)	5.0 (3.0, 11.0)	0.69
Length of hospital stay (days) c	16.0 (11.5, 31.0)	18.0 (13.0, 32.0)	0.12
Died in hospital	11 (5.2)	3 (3.5)	0.52

CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; PRBCs, packed red blood cells.

Data are n (%) or median (Q1, Q3). Shorter: discontinued anti-fibrotic medication ⩽ 5 medication half-lives before transplant; longer: discontinued anti-fibrotic medication > 5 medication half-lives before transplant.

^aAmong patients who received intra-operative PRBCs.

^bAmong patients who received post-operative PRBCs.

^cAmong 283 patients who survived to discharge.